Is a cure on the horizon for hepatitis B? New drug offers hope, but there's a 'long way to go'

Health Canada has approved a new drug that offers a functional cure for chronic hepatitis B, with a rollout expected in 2027. While experts call it a major advancement, they caution that it is only effective for a subset of patients and raises concerns regarding cost and long-term accessibility.
Why it matters
Hepatitis B remains a significant global health threat, and this breakthrough represents the first potential functional cure for a disease that causes chronic liver damage and cancer.
Despite decades of efforts to wipe out hepatitis B, the viral liver infection remains a quiet threat — and one that's long lacked a cure.
While rates have dropped dramatically since the rise of childhood vaccination programs, an estimated 260,000 Canadians are still living with the virus, including roughly half who don't know they're infected . Over time, many of those silently carrying the virus go on to develop a range of life-threatening issues, including cancer or sudden liver failure.
Could a long-awaited cure finally be in sight?
In early November, Health Canada approved a breakthrough drug offering the first "functional cure" for a portion of chronic hepatitis B patients, which drugmaker GSK expect to roll out in early 2027 .
Dr. Carla Coffin, a hepatologist and professor at the University of Calgary's Cumming School of Medicine, calls it a "major step forward."
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in